GSC
PTCT icon

Ground Swell Capital’s PTC Therapeutics PTCT Stock Holding History

Ground Swell Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-100
Closed -$3K – 2691
2014
Q2 		$3K Buy
+100
New +$2.14K 0.01% 1331

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ground Swell Capital's PTCT Position: Q3 2014 in Review

Ground Swell Capital sold out of PTC Therapeutics (PTCT) in Q3 2014, closing a stake of 100 shares — an estimated $3K sold.

Ground Swell Capital first reported a position in PTCT in Q2 2014 and held it in 1 quarter. The position peaked at $3K in Q2 2014. 99 funds tracked by Wall St. Rank hold PTCT as of Q3 2014.

  • Ground Swell Capital reported no remaining PTC Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Ground Swell Capital sold 100 PTC Therapeutics shares in Q3 2014, an estimated $3K.
  • Ground Swell Capital first reported a position in PTC Therapeutics in Q2 2014 and held it in 1 quarter.
  • Ground Swell Capital's PTC Therapeutics position peaked at $3K in Q2 2014.
  • 99 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.